People's State of Bavaria

TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation

Retrieved on: 
Tuesday, December 6, 2022
Physician, Surgeon, Quality of life, Heart, Clinical trial, Mortality, Minimally invasive procedure, TR, Series, Wellington Partners, Capital, SAS, IDE, Prognosis, Trial of the century, Valvular heart disease, People's State of Bavaria, Survival, Tricare, General partnership, Research, Disease, Tricuspid valve, Risk, Blood, Patient, Pharmaceutical industry, Medical imaging, Health insurance, Topaz

TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation

Key Points: 
  • TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation
    Paris, France and Munich, Germany, December 6, 2022 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today the second closing and completion of its Series C financing round, successfully raising a total of €51m for the round.
  • Topaz is an innovative device developed to help patients suffering from severe tricuspid regurgitation without the need for open heart surgery.
  • Tricuspid regurgitation occurs when the tricuspid valve fails to close properly, causing blood to flow backwards into the right atrium.
  • Therefore, physicians are urgently seeking minimally invasive, low-risk solutions to improve clinical outcomes in TR patients.

Ethris Receives “Most Innovative Product Top 3” Award for COVID-19 Therapeutic Candidate at 22nd Pharma Trend Image & Innovation Award

Retrieved on: 
Wednesday, September 15, 2021
Health, Infectious Diseases, Genetics, Research, Science, Pharmaceutical, Biotechnology, Gesellschaft mit beschränkter Haftung, Innovation, Respiratory system, Science, Deutsches Museum, Biotechnology, CEO, Coronavirus, People's State of Bavaria, Gene, III, Association, Innovative Products of America, Severe acute respiratory syndrome coronavirus 2, Therapy, Bundesverband der Pharmazeutischen Industrie, Rx, COVID-19, RNA, RNA transfection, OTC, Research, Lung, Pharmaceutical industry, Vaccine

Ethris GmbH announced today that its lead COVID-19 therapeutic candidate, ETH47, has been awarded "Most Innovative Product Top 3" in the category of Leap Innovations at the Pharma Trend Image & Innovation Awards 2021.

Key Points: 
  • Ethris GmbH announced today that its lead COVID-19 therapeutic candidate, ETH47, has been awarded "Most Innovative Product Top 3" in the category of Leap Innovations at the Pharma Trend Image & Innovation Awards 2021.
  • ETH47 is a therapeutic candidate that harbors the mRNA blueprint for type III interferon.
  • The prize was presented to Dr. Carsten Rudolph, CEO of Ethris, at a ceremony on September 14, 2021 at the Deutches (German) Museum in Munich, Germany.
  • Ethris has paved a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA technology platform to discover, design and develop innovative therapies.

Ballard Receives Order for Fuel Cell Modules to Power Trial Operation of Siemens Mireo Plus H Train

Retrieved on: 
Thursday, July 15, 2021
Rail transport, High-speed rail by country, Manufacturing, Siemens, Siemens Mobility, High-speed trains, Ballard Power Systems, Intercity Express, Ballard, Siemens Mireo

VANCOUVER, BC, July 15, 2021 /PRNewswire/ -Ballard Power Systems (NASDAQ: BLDP) (TSX: BLDP) today announced that it has received a purchase order for two of its 200-kilowatt (kW) fuel cell modules from Siemens Mobility GmbH ("Siemens"; www.siemens.com ) to power a 2-car Mireo Plus H passenger train through a trial operation in Bavaria, Germany.

Key Points: 
  • VANCOUVER, BC, July 15, 2021 /PRNewswire/ -Ballard Power Systems (NASDAQ: BLDP) (TSX: BLDP) today announced that it has received a purchase order for two of its 200-kilowatt (kW) fuel cell modules from Siemens Mobility GmbH ("Siemens"; www.siemens.com ) to power a 2-car Mireo Plus H passenger train through a trial operation in Bavaria, Germany.
  • As per Ballard's announcement in November 2017, the 200kW fuel cell module has been developed and tested under a multi-year Development Agreement with Siemens, in order to provide primary propulsion power for the Mireo Plus H light rail train.
  • Ballard plans to deliver the modules ordered by Siemens for the trial operation in Bavaria in 2022.
  • Rob Campbell, Ballard Chief Commercial Officer noted, "The trial operation in Bavaria is an exciting development in our ongoing work with Siemens for its Mireo Plus H passenger train.